ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches
Strong financials and pipeline momentum highlighted, with recent FDA approval for LISRAYA and best-in-class data for mosliciguat in PH-ILD. Multiple late-stage trials and launches are expected in the next year, targeting significant unmet needs in rare and underserved diseases.Based on Roivant Scie…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.